Biotech Superstar Dies

Alejandro Zaffaroni, who launched companies that developed birth control pills, microarrays, and transdermal drug patches, has died at age 91.  

By | March 7, 2014

ZAFFARONI FOUNDATIONA successful biotech entrepreneur whose companies pioneered the technology behind transdermal patches, DNA chips, and the birth control pill, died at his home in California at the age of 91. Alejandro Zaffaroni was the man behind Alza, Affymetrix, Affymax, and many other successful firms. “He always started with a big idea behind his companies and then adapted on the ground to the reality of what could be achieved,” Isaac Stein, a business partner of Zaffaroni, told The New York Times.

According to the Times, Zaffaroni was born in Uruguay and became an orphan at age 18. He came to the U.S. for his graduate work in biochemistry on corticosteroids. During the 1950s and '60s he became an accomplished scientist at Syntex Pharmaceuticals. Writing for The Scientist in 1988, David Moreau, the first managing director of Syntex in the U.K., described how Zaffaroni’s advances in paper chromatography of steroids contributed to the development of “fluocinolone acetonide (known worldwide as Synalar), the oral progestins that made the birth-control pill possible, non-virilizing androgens such as oxymetholone (still used for the treatment of aplastic anemia), paramethasone and many others.”

Zaffaroni’s business acumen and congenial nature helped him to lure successful academics to biotechnology. “It’s ironic,” J. Leighton Read told The Scientist in 1989 when he was Affymax’s chief operating officer, “but it’s often more collaborative and more multidisciplinary here than what people experience in their academic departments.”

In 1995, Zaffaroni earned the National Medal of Technology and Innovation and in 2006 he established a $10 million scholarship fund at Stanford University for Latin American students. In speaking with the Times this week, Samuel Colella, a venture capitalist who invested in some of Zaffaroni’s companies, called him “one of the kindest, gentlest, most humane individuals that I think I’ve ever met.”

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. How Plants Evolved Different Ways to Make Caffeine
  3. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech